{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:37:56Z","timestamp":1784745476786,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.urology.2022.11.053","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T20:49:14Z","timestamp":1675975754000},"page":"106-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Fumarate Hydratase Variants and Their Association With Paraganglioma\/Pheochromocytoma"],"prefix":"10.1016","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9487-8807","authenticated-orcid":false,"given":"Shirin","family":"Zavoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avital","family":"Harari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Hatchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Esplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Nykamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Christofk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2065-3570","authenticated-orcid":false,"given":"Brian","family":"Shuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2022.11.053_bib0001","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2022.11.053_bib0002","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjsurg.2010.04.012","article-title":"Malignant pheochromocytoma: a review","volume":"201","author":"Harari","year":"2011","journal-title":"Am J Surg"},{"key":"10.1016\/j.urology.2022.11.053_bib0003","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urology.2022.11.053_bib0004","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.urology.2022.11.053_bib0005","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2022.11.053_bib0006","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1210\/jc.2008-2419","article-title":"Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and\/or functional or nonfunctional paragangliomas","volume":"94","author":"Mannelli","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2022.11.053_bib0007","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","article-title":"Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase","volume":"7","author":"Selak","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urology.2022.11.053_bib0008","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.urology.2014.01.007","article-title":"The genetic basis of pheochromocytoma and paraganglioma: implications for management","volume":"83","author":"Shuch","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.urology.2022.11.053_bib0009","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41588-018-0170-4","article-title":"Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair","volume":"50","author":"Sulkowski","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.urology.2022.11.053_bib0010","series-title":"GeneReviews","article-title":"Fumarate Hydratase Deficiency","author":"Coleman","year":"2006"},{"key":"10.1016\/j.urology.2022.11.053_bib0011","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1073\/pnas.051633798","article-title":"Inherited susceptibility to uterine leiomyomas and renal cell cancer","volume":"98","author":"Launonen","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urology.2022.11.053_bib0012","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/PAS.0b013e31804375b8","article-title":"The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome","volume":"31","author":"Merino","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urology.2022.11.053_bib0013","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.juro.2012.07.139","article-title":"Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer","volume":"189","author":"Shuch","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.11.053_bib0014","doi-asserted-by":"crossref","first-page":"E2046","DOI":"10.1210\/jc.2014-1659","article-title":"Germline FH mutations presenting with pheochromocytoma","volume":"99","author":"Clark","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2022.11.053_bib0015","series-title":"GeneReviews","article-title":"FH Tumor Predisposition Syndrome","author":"Kamihara","year":"2006"},{"key":"10.1016\/j.urology.2022.11.053_bib0016","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cge.13014","article-title":"Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers","volume":"92","author":"Muller","year":"2017","journal-title":"Clin Genet"},{"key":"10.1016\/j.urology.2022.11.053_bib0017","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41436-018-0106-5","article-title":"Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma","volume":"21","author":"Richter","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.urology.2022.11.053_bib0018","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10689-014-9735-2","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment","volume":"13","author":"Menko","year":"2014","journal-title":"Fam Cancer"},{"key":"10.1016\/j.urology.2022.11.053_bib0019","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1002\/cncr.32914","article-title":"Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer","volume":"126","author":"Shuch","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2022.11.053_bib0020","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cncr.33997","article-title":"Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing","volume":"128","author":"Lu","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2022.11.053_bib0021","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/gim.2017.37","article-title":"Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria","volume":"19","author":"Nykamp","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.urology.2022.11.053_bib0022","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urology.2022.11.053_bib0023","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.urology.2022.11.053_bib0024","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.urology.2022.11.053_bib0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/humu.23900","article-title":"Fumarate hydratase FH c.1431 (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma","volume":"41","author":"Zhang","year":"2020","journal-title":"Hum Mutat"},{"key":"10.1016\/j.urology.2022.11.053_bib0026","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/cdd.2015.53","article-title":"TP53: an oncogene in disguise","volume":"22","author":"Soussi","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.urology.2022.11.053_bib0027","doi-asserted-by":"crossref","first-page":"eaal2463","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.urology.2022.11.053_bib0028","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/jamaoncol.2018.0340","article-title":"National distribution of cancer genetic testing in the United States: evidence for a gender disparity in hereditary breast and ovarian cancer","volume":"4","author":"Childers","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urology.2022.11.053_bib0029","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.otohns.2007.01.015","article-title":"Malignant head and neck paragangliomas in SDHB mutation carriers","volume":"137","author":"Boedeker","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.urology.2022.11.053_bib0030","unstructured":"National Comprehensive Cancer Network. Kidney Cancer (Version 4.2022)"},{"key":"10.1016\/j.urology.2022.11.053_bib0031","series-title":"GeneReviews","article-title":"Hereditary Paraganglioma-Pheochromocytoma Syndromes","author":"Else","year":"2008"},{"key":"10.1016\/j.urology.2022.11.053_bib0032","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429523000547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429523000547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:06:52Z","timestamp":1758769612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429523000547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":32,"alternative-id":["S0090429523000547"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2022.11.053","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fumarate Hydratase Variants and Their Association With Paraganglioma\/Pheochromocytoma","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2022.11.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}